Recursion
@recursionpharma.bsky.social
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here. Learn more at recursion.com #techbio
See you at #SLAS2026! Two of our AI drug discovery experts are presenting at the SLAS International Conference & Exhibition Feb. 7-11 in Boston - on Industrializing Drug Discovery with ML and Leveraging AI to Map Cellular Morphology Across Imaging Modalities. www.slas.org/events-calen...
January 28, 2026 at 2:19 PM
See you at #SLAS2026! Two of our AI drug discovery experts are presenting at the SLAS International Conference & Exhibition Feb. 7-11 in Boston - on Industrializing Drug Discovery with ML and Leveraging AI to Map Cellular Morphology Across Imaging Modalities. www.slas.org/events-calen...
A new episode of Google’s podcast #WhereTheInternetLives looks at Recursion's approach to making new medicines – relying on massive proprietary datasets spanning biology, chemistry and patient data; supercomputing; and an end-to-end AI platform. www.youtube.com/watch?v=o-8W... #GoogleDataCenters
Mapping New Medicines | Where the Internet Lives
YouTube video by Google
www.youtube.com
January 27, 2026 at 2:00 PM
A new episode of Google’s podcast #WhereTheInternetLives looks at Recursion's approach to making new medicines – relying on massive proprietary datasets spanning biology, chemistry and patient data; supercomputing; and an end-to-end AI platform. www.youtube.com/watch?v=o-8W... #GoogleDataCenters
Leveraging AI & real-world patient data to accelerate drug discovery. In a recent webinar, Sid Jain and Hayley Donnella of Recursion spoke to Shane Woods at Tempus AI about how patient data is driving the latest advances in AI drug discovery. www.tempus.com/resources/co... #TechBio #data 🧪
January 9, 2026 at 3:40 PM
Leveraging AI & real-world patient data to accelerate drug discovery. In a recent webinar, Sid Jain and Hayley Donnella of Recursion spoke to Shane Woods at Tempus AI about how patient data is driving the latest advances in AI drug discovery. www.tempus.com/resources/co... #TechBio #data 🧪
Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP), which offers new hope for patients. www.youtube.com/watch?v=mv0c...
Recursion's Positive Phase 1b/2 Results from the Ongoing TUPELO Study of REC-4881 for FAP
YouTube video by Recursion
www.youtube.com
December 10, 2025 at 6:40 PM
Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP), which offers new hope for patients. www.youtube.com/watch?v=mv0c...
🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological & chemical datasets, AI models & one of the industry’s most powerful supercomputers. Learn about our progress & what's next: www.recursion.com/news/since-i... #virtualcell
December 4, 2025 at 4:51 PM
🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological & chemical datasets, AI models & one of the industry’s most powerful supercomputers. Learn about our progress & what's next: www.recursion.com/news/since-i... #virtualcell
🚀 The energy & momentum happening around life sciences in London – fueled by innovation and investment in #AI – is undeniable, and it was on full display last week at the Jefferies Global Healthcare Conference & London Life Sciences Week presentations and events. www.youtube.com/shorts/r2iwx...
AI in Life Sciences Momentum in London: Recursion at Jefferies and London Life Sciences Week
YouTube video by Recursion
www.youtube.com
November 24, 2025 at 2:28 PM
🚀 The energy & momentum happening around life sciences in London – fueled by innovation and investment in #AI – is undeniable, and it was on full display last week at the Jefferies Global Healthcare Conference & London Life Sciences Week presentations and events. www.youtube.com/shorts/r2iwx...
In a new story in Technology Networks, incoming CEO and President Najat Khan shared insights into the creation of the Microglia Map in partnership with Roche and Genentech and what it could mean for future drug discovery. #neuroscience #microglia #TechBio www.technologynetworks.com/drug-discove...
Mapping Microglia To Unlock New Paths in Neuroscience
Dr. Najat Khan of Recursion shared insights into the creation of the Microglia Map and what it could mean for future drug discovery.
www.technologynetworks.com
November 21, 2025 at 2:23 PM
In a new story in Technology Networks, incoming CEO and President Najat Khan shared insights into the creation of the Microglia Map in partnership with Roche and Genentech and what it could mean for future drug discovery. #neuroscience #microglia #TechBio www.technologynetworks.com/drug-discove...
In a new video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts: “What is one thing you wish your families understood about the work that you do?” For many, it’s all about the patients.
#onething #Recursionaut #culture #TechBio #drugdiscovery
www.youtube.com/shorts/ougrI...
#onething #Recursionaut #culture #TechBio #drugdiscovery
www.youtube.com/shorts/ougrI...
One Thing I Wish My Family Understood About My Work at Recursion
YouTube video by Recursion
www.youtube.com
November 18, 2025 at 7:29 PM
In a new video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts: “What is one thing you wish your families understood about the work that you do?” For many, it’s all about the patients.
#onething #Recursionaut #culture #TechBio #drugdiscovery
www.youtube.com/shorts/ougrI...
#onething #Recursionaut #culture #TechBio #drugdiscovery
www.youtube.com/shorts/ougrI...
Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research.
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
November 12, 2025 at 2:47 PM
Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research.
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx
November 10, 2025 at 2:22 PM
At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx
Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...
November 6, 2025 at 3:34 PM
Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...
In our latest Explain the Impact video, we share the inside story of the world's first Microglia Map from Recursion and Roche and Genentech to help unlock new targets in neurodegenerative diseases. #neuroscience #techbio youtube.com/shorts/xvPIQ...
The Making of the World's First Microglia Map to Explore New Targets for Neurological Diseases
YouTube video by Recursion
youtube.com
November 4, 2025 at 1:47 PM
In our latest Explain the Impact video, we share the inside story of the world's first Microglia Map from Recursion and Roche and Genentech to help unlock new targets in neurodegenerative diseases. #neuroscience #techbio youtube.com/shorts/xvPIQ...
💥 Recursion has achieved a $30 million milestone payment from its partners, Roche and Genentech, following the acceptance of the Microglia Map – a first-of-its-kind whole genome map of the brain’s immune cells.
👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio
👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio
How a First-of-its-Kind “Microglia Map” from Recursion and Roche and Genentech Could Unlock New Treatments for Neurodegenerative Diseases
A first-of-its-kind whole genome map from researchers at Recursion with partners Roche and Genentech offers a new approach to exploring novel targets and pathways for a wide range of neurological dise...
www.recursion.com
October 31, 2025 at 2:46 PM
💥 Recursion has achieved a $30 million milestone payment from its partners, Roche and Genentech, following the acceptance of the Microglia Map – a first-of-its-kind whole genome map of the brain’s immune cells.
👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio
👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio
The 3rd episode of TechBio Talks is now live, featuring leading AI investor Nathan Benaich of Air Street Capital with host Chris Gibson discussing the evolving landscape of AI in drug discovery, the biggest trends in Nathan’s new State of AI Report, and more! www.youtube.com/watch?v=MUjT...
TechBio Talks Episode 3: Air Street Capital's Nathan Benaich with Host Chris Gibson
YouTube video by Recursion
www.youtube.com
October 28, 2025 at 4:45 PM
The 3rd episode of TechBio Talks is now live, featuring leading AI investor Nathan Benaich of Air Street Capital with host Chris Gibson discussing the evolving landscape of AI in drug discovery, the biggest trends in Nathan’s new State of AI Report, and more! www.youtube.com/watch?v=MUjT...
What gets you excited?
In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture
www.youtube.com/shorts/zQDQq...
In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture
www.youtube.com/shorts/zQDQq...
One Thing That Makes Me Excited to Come to Work at Recursion
YouTube video by Recursion
www.youtube.com
October 16, 2025 at 1:42 PM
What gets you excited?
In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture
www.youtube.com/shorts/zQDQq...
In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture
www.youtube.com/shorts/zQDQq...
Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."
October 15, 2025 at 2:23 PM
Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."
🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪
October 13, 2025 at 3:24 PM
Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
October 6, 2025 at 1:49 PM
Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
October 2, 2025 at 1:34 PM
Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
In a clip from our podcast TechBio Talks, MIT's Regina Barzilay tells host Najat Khan how we can leverage machine learning to better predict how a patient will respond to treatments, to improve his or her condition for the “longest time with minimal side effects.” www.youtube.com/shorts/uSEM1... 🧵
Using Machine Learning to Predict Patient Response to Treatment
YouTube video by Recursion
www.youtube.com
September 23, 2025 at 1:53 PM
In a clip from our podcast TechBio Talks, MIT's Regina Barzilay tells host Najat Khan how we can leverage machine learning to better predict how a patient will respond to treatments, to improve his or her condition for the “longest time with minimal side effects.” www.youtube.com/shorts/uSEM1... 🧵
We♥️our innovators.
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
September 22, 2025 at 1:48 PM
We♥️our innovators.
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...
September 18, 2025 at 1:29 PM
A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...
“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones
👉 event.webcasts.com/viewer/event...
👉 event.webcasts.com/viewer/event...
September 16, 2025 at 2:15 PM
“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones
👉 event.webcasts.com/viewer/event...
👉 event.webcasts.com/viewer/event...
A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment.
👉 www.ft.com/content/9a8a...
👉 www.ft.com/content/9a8a...
September 15, 2025 at 2:41 PM
A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment.
👉 www.ft.com/content/9a8a...
👉 www.ft.com/content/9a8a...